- Fellowship: Washington University School of Medicine (Gynecologic Oncology)
- Residency: Good Samaritan Hospital (Obstetrics and Gynecology)
- Medical Degree: University of Cincinnati (Obstetrics and Gynecology Gynecologic Oncology)
- Bachelor's Degree: Miami University (Zoology)
American Board of Obstetrics and Gynecology (Gynecologic Oncology) (Certification Date: 1997-04-09) - (Recertification Date: 2024-12-31)
American Board of Obstetrics and Gynecology (Certification Date: 1995-11-17) - (Recertification Date: 2024-12-31)
Gynecologic Oncology
Obstetrics and Gynecology
- Medical Sciences Building 2005H
- Email herzogtj@ucmail.uc.edu
Clinical Interests
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Adenomyosis
Adnexal Disease
Adnexal Tumors
Cervical Cancer
Dysgerminoma
Embryonal Carcinoma
Embryonal Tumors
Endometrial Cancer
Endometrial Stromal Sarcoma
Endometriosis
Fallopian Tube Cancer
Fibroids
Germ Cell and Embryona Cancers
Germ Cell Tumor
Gestational Trophoblastic Neoplasia
Human Papilloma Virus (HPV)
Krukenberg Tumor
Other Complicated Gynecologic Cancers
Ovarian Cancer
Ovarian Cyst
Pelvic Cancers
Pelvic Masses
Placenta Accreta
Precancer in the Vagina
Precancer in the Vulva
Precancers in the Cervix
Uterine Fibroids (Uterine leiomyoma)
Uterine Hemorrhage
Uterine Polyps (Endometrial Polyps)
Uterine Sarcoma
Vaginal Cancer
Vulvar Cancer
Peer Reviewed Publications
Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. 10-20-2014. Incorporation of pazopanib in maintenance therapy of ovarian cancer Journal of Clinical Oncology, 32 30, 3374-3381
Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. 05-01-2015. In assessing surrogate clinical trial end points: Drug safety is a requisite Journal of Clinical Oncology, 33 13, 1511-1512
Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. 01-01-2015. Progression-free survival by local investigator versus independent central review: Comparative analy Gynecologic Oncology, 136 1, 37-42
Jackson A.;Eisenhauer E.;Herzog T. 01-01-2015. Emerging therapies: Angiogenesis inhibitors for ovarian cancer Expert Opinion on Emerging Drugs, 20 2, 331-346
Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. 01-01-2015. Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca Gynecologic Oncology, 138 2, 267-271
Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. 01-01-2014. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian International Journal of Gynecological Cancer, 24 9, 1583-1589
Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. 01-01-2014. Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc Gynecologic Oncology, 135 3, 625
Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. 01-01-2014. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer Gynecologic Oncology, 132 3, 517-525
Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. 01-01-2014. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer, 120 8, 1246-1254